AstraZeneca Downgraded to “Underperform” at Jefferies Group (AZN)
AstraZeneca (LON:AZN) was downgraded by investment analysts at Jefferies Group from a “hold” rating to an “underperform” rating in a note issued to investors on Friday, American Banking & Market News reports.
Shares of AstraZeneca (LON:AZN) traded up 1.39% on Friday, hitting GBX 3176.50. The stock had a trading volume of 2,038,526 shares. AstraZeneca has a one year low of GBX 2786.00 and a one year high of GBX 3544.50. The stock’s 50-day moving average is GBX 3215.42 and its 200-day moving average is GBX 3252.57. The company’s market cap is £39.770 billion.
Other equities research analysts have also recently issued reports about the stock. Analysts at AlphaValue reiterated a “reduce” rating on shares of AstraZeneca in a research note to investors on Thursday. They now have a GBX 3,213 ($51.55) price target on the stock. Separately, analysts at Bryan Garnier & Cie reiterated a “buy” rating on shares of AstraZeneca in a research note to investors on Monday. They now have a GBX 3,620 ($58.08) price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of AstraZeneca in a research note to investors on Tuesday, October 1st. They now have a GBX 3,300 ($52.94) price target on the stock. Twelve equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of GBX 3,100.38 ($49.74).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.